United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
529.17
+51.01 (10.67%)
At close: Mar 9, 2026, 4:00 PM EDT
533.00
+3.83 (0.72%)
After-hours: Mar 9, 2026, 7:59 PM EDT
United Therapeutics Revenue by Segment
History
| Date | Tyvaso | Remodulin | Orenitram | Unituxin | Adcirca | Other |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | 1.88B | 526.80M | 496.90M | 226.80M | 30.00M | 24.00M |
| Sep 30, 2025 | 1.83B | 533.30M | 483.50M | 232.00M | 26.90M | 22.90M |
| Jun 30, 2025 | 1.79B | 535.70M | 465.60M | 245.20M | 24.20M | 21.50M |
| Mar 31, 2025 | 1.71B | 548.30M | 448.80M | 238.50M | 23.40M | 20.90M |
| Dec 31, 2024 | 1.62B | 538.10M | 434.30M | 238.70M | 23.80M | 22.10M |
| Sep 30, 2024 | 1.56B | 518.70M | 410.60M | 225.40M | 25.90M | 20.50M |
| Jun 30, 2024 | 1.45B | 521.50M | 389.40M | 215.60M | 26.20M | 16.90M |
| Mar 31, 2024 | 1.37B | 501.40M | 377.40M | 208.20M | 28.00M | 14.50M |
| Dec 31, 2023 | 1.23B | 494.80M | 359.40M | 198.90M | 28.90M | 12.10M |
| Sep 30, 2023 | 1.13B | 502.20M | 351.10M | 181.40M | 32.50M | 18.20M |
| Jun 30, 2023 | 1.06B | 485.10M | 346.60M | 176.20M | 35.90M | - |
| Mar 31, 2023 | 939.40M | 489.90M | 330.50M | 176.40M | 38.80M | - |
| Dec 31, 2022 | 873.00M | 500.20M | 325.10M | 182.90M | 41.30M | - |
| Sep 30, 2022 | 797.20M | 496.00M | 321.60M | 196.20M | 39.00M | - |
| Jun 30, 2022 | 703.70M | 507.40M | 319.30M | 205.40M | 42.90M | - |
| Mar 31, 2022 | 656.50M | 515.20M | 316.50M | 214.00M | 56.10M | - |
| Dec 31, 2021 | 607.50M | 513.70M | 306.10M | 202.30M | 55.90M | - |
| Sep 30, 2021 | 572.70M | 523.30M | 307.80M | 182.00M | 69.40M | - |
| Jun 30, 2021 | 538.00M | 522.40M | 297.30M | 164.30M | 68.60M | - |
| Mar 31, 2021 | 503.40M | 501.60M | 296.50M | 140.20M | 64.40M | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.